REV-ERBα mediates complement expression and diurnal regulation of microglial synaptic phagocytosis

  1. Percy Griffin
  2. Patrick W Sheehan
  3. Julie M Dimitry
  4. Chun Guo
  5. Michael F Kanan
  6. Jiyeon Lee
  7. Jinsong Zhang
  8. Erik Steven Musiek  Is a corresponding author
  1. Washington University School of Medicine in St. Louis, United States
  2. Saint Louis University School of Medicine, United States

Abstract

The circadian clock regulates various aspects of brain health including microglial and astrocyte activation. Here we report that deletion of the master clock protein BMAL1 in mice robustly increases expression of complement genes, including C4b and C3, in the hippocampus. BMAL1 regulates expression of the transcriptional repressor REV-ERBa, and deletion of REV-ERBa causes increased expression of C4b transcript in neurons and astrocytes as well as C3 protein primarily in astrocytes. REV-ERBa deletion increased microglial phagocytosis of synapses and synapse loss in the CA3 region of the hippocampus. Finally, we observed diurnal variation in the degree of microglial synaptic phagocytosis which was antiphase to REV-ERBα expression. This daily variation in microglial synaptic phagocytosis was abrogated by global REV-ERBα deletion, which caused persistently elevated synaptic phagocytosis. This work uncovers the BMAL1-REV-ERBa axis as a regulator of complement expression and synaptic phagocytosis in the brain, linking circadian proteins to synaptic regulation.

Data availability

The microarray data used in Fig. 1 is available on ArrayExpress E-MTAB-7590 and E-MTAB-7151.We have also uploaded all of the raw data from all of the figures in the paper as Source Files and to Dryad, which is available at: https://doi.org/10.5061/dryad.nzs7h44p1.This includes all of the image quantification data. Raw image files were not uploaded, as there are several hundred and they exceed 20GB.

The following previously published data sets were used

Article and author information

Author details

  1. Percy Griffin

    Neurology, Washington University School of Medicine in St. Louis, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Patrick W Sheehan

    Neurology, Washington University School of Medicine in St. Louis, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Julie M Dimitry

    Neurology, Washington University School of Medicine in St. Louis, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Chun Guo

    Pharmacology and Physiological Sciences, Saint Louis University School of Medicine, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Michael F Kanan

    Neurology, Washington University School of Medicine in St. Louis, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Jiyeon Lee

    Neurology, Washington University School of Medicine in St. Louis, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Jinsong Zhang

    Pharmacology and Physiological Sciences, Saint Louis University School of Medicine, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Erik Steven Musiek

    Neurology, Washington University School of Medicine in St. Louis, St. Louis, United States
    For correspondence
    musieke@wustl.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8873-0360

Funding

National Institute on Aging (R01AG054517)

  • Erik Steven Musiek

National Institute on Aging (R01AG063743)

  • Erik Steven Musiek

Cure Alzheimer's Fund (Investigator award)

  • Erik Steven Musiek

Coins for Alzheimer's Research Trust (Investigator award)

  • Erik Steven Musiek

National Science Foundation (DGE- 1745038)

  • Percy Griffin

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Louis J Ptáček, University of California, San Francisco, United States

Ethics

Animal experimentation: All experiments were conducted in accordance with recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, and were approved by the institutional animal care and use committee (IACUC) at Washington University under protocol 2017-0124 (E. Musiek, PI).

Version history

  1. Received: May 10, 2020
  2. Accepted: November 27, 2020
  3. Accepted Manuscript published: December 1, 2020 (version 1)
  4. Version of Record published: December 10, 2020 (version 2)

Copyright

© 2020, Griffin et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,486
    views
  • 402
    downloads
  • 44
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Percy Griffin
  2. Patrick W Sheehan
  3. Julie M Dimitry
  4. Chun Guo
  5. Michael F Kanan
  6. Jiyeon Lee
  7. Jinsong Zhang
  8. Erik Steven Musiek
(2020)
REV-ERBα mediates complement expression and diurnal regulation of microglial synaptic phagocytosis
eLife 9:e58765.
https://doi.org/10.7554/eLife.58765

Share this article

https://doi.org/10.7554/eLife.58765

Further reading

    1. Developmental Biology
    2. Neuroscience
    Melody C Iacino, Taylor A Stowe ... Mark J Ferris
    Research Article

    Adolescence is characterized by changes in reward-related behaviors, social behaviors, and decision making. These behavioral changes are necessary for the transition into adulthood, but they also increase vulnerability to the development of a range of psychiatric disorders. Major reorganization of the dopamine system during adolescence is thought to underlie, in part, the associated behavioral changes and increased vulnerability. Here, we utilized fast scan cyclic voltammetry and microdialysis to examine differences in dopamine release as well as mechanisms that underlie differential dopamine signaling in the nucleus accumbens (NAc) core of adolescent (P28-35) and adult (P70-90) male rats. We show baseline differences between adult and adolescent stimulated dopamine release in male rats, as well as opposite effects of the a6 nicotinic acetylcholine receptor (nAChR) on modulating dopamine release. The a6-selective blocker, a-conotoxin, increased dopamine release in early adolescent rats, but decreased dopamine release in rats beginning in middle adolescence and extending through adulthood. Strikingly, blockade of GABAA and GABAB receptors revealed that this a6-mediated increase in adolescent dopamine release requires NAc GABA signaling to occur. We confirm the role of a6 nAChR and GABA in mediating this effect in vivo using microdialysis. Results herein suggest a multisynaptic mechanism potentially unique to the period of development that includes early adolescence, involving acetylcholine acting at a6-containing nAChRs to drive inhibitory GABA tone on dopamine release.

    1. Neuroscience
    Jongkyun Kang, Guodong Huang ... Jie Shen
    Research Article

    Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of Parkinson’s disease (PD). However, whether LRRK2 mutations cause PD and degeneration of dopaminergic (DA) neurons via a toxic gain-of-function or a loss-of-function mechanism is unresolved and has pivotal implications for LRRK2-based PD therapies. In this study, we investigate whether Lrrk2 and its functional homolog Lrrk1 play a cell-intrinsic role in DA neuron survival through the development of DA neuron-specific Lrrk conditional double knockout (cDKO) mice. Unlike Lrrk germline DKO mice, DA neuron-restricted Lrrk cDKO mice exhibit normal mortality but develop age-dependent loss of DA neurons, as shown by the progressive reduction of DA neurons in the substantia nigra pars compacta (SNpc) at the ages of 20 and 24 months. Moreover, DA neurodegeneration is accompanied with increases in apoptosis and elevated microgliosis in the SNpc as well as decreases in DA terminals in the striatum, and is preceded by impaired motor coordination. Taken together, these findings provide the unequivocal evidence for the cell-intrinsic requirement of LRRK in DA neurons and raise the possibility that LRRK2 mutations may impair its protection of DA neurons, leading to DA neurodegeneration in PD.